Rapamycin also known as sirolimus is an immunosuppressive drug that belongs to the class of mtor inhibitors. It works by binding to the intracellular protein fkbp12 which then interacts with the mechanistic target of Rapamycin complex 1. The mtorc1 complex regulates cell growth proliferation and metabolism through signaling pathways. By inhibiting this complex Rapamycin reduces the translation of proteins that drive cell proliferation and immune activation. This inhibition leads to a decrease in t cell proliferation and antibody production which contributes to its immunosuppressive effects. Clinically the drug is used to prevent organ transplant rejection and to treat certain malignancies such as renal cell carcinoma. It also has antiproliferative properties that can modulate vascular smooth muscle cell growth and may impact angiogenesis. The overall therapeutic effect stems from the suppression of signaling cascades that sustain immune responses and tumor cell survival.

Rapamycin is a naturally derived macrolide that functions as an immunosuppressive agent by targeting a cellular protein known as mtor. The drug binds to fkbp12 creating a complex that blocks downstream signaling pathways that drive cell growth and immune activation. This inhibition prevents the transcription of genes required for t cell proliferation and cytokine production which are central to graft rejection and inflammatory responses. Clinically it is employed to maintain graft tolerance after organ transplantation and to treat certain malignancies that rely on uncontrolled proliferation. In addition to transplantation it is used for managing autoimmune conditions such as lupus nephritis where excessive immune activity damages tissues. The therapeutic effect arises from the disruption of mtor complex 1 which regulates nutrient sensing and protein synthesis governing cell cycle progression. By halting these pathways the medication reduces activation of immune cells and limits the expansion of cancerous cells. Its pharmacokinetic profile includes oral absorption with hepatic metabolism and elimination that supports sustained systemic exposure needed for chronic therapy.

Rapamycin is an immunosuppressive drug originally developed to prevent organ transplant rejection and later studied for anticancer and anti-aging uses. Common adverse effects include mouth ulcers and skin rash that may appear during the early weeks of treatment. Blood tests often show elevated cholesterol levels and an increase in triglyceride concentrations which can persist while the medication is taken. The drug can cause delayed wound healing which means surgical incisions or cuts may take longer to close. Because Rapamycin inhibits mtor signaling it may affect glucose metabolism leading to higher blood sugar or new-onset diabetes in some patients. Some individuals experience reduced appetite and weight loss due to gastrointestinal discomfort. Rarely the medication has been linked to interstitial lung changes which appear as subtle scarring on imaging without obvious symptoms. Long-term use can also suppress the immune response making vaccinated individuals less likely to develop a full protective antibody response.

Rapamycin can affect the immune system by reducing the activity of certain white blood cells. Some people experience changes in blood lipid levels such as increased cholesterol or triglycerides. It may cause mouth sores or inflammation of the lining inside the mouth. Occasionally it can lead to swelling of the hands or feet due to fluid retention. In rare cases it may influence blood sugar regulation potentially raising glucose levels. These effects are generally observed during treatment and may vary among individuals.